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o r i g i n a l a r t i c l e
Assessing the Burden of Healthcare-Associated Infections
through Prevalence Studies: What Is the Best Method?
Walter Zingg, MD;1 Benedikt D. Huttner, MD, MS;1 Hugo Sax, MD;1,a Didier Pittet, MD, MS1
objective. To explore differences in the prevalence of healthcare-associated infections (HAIs) according to survey methodology.
design. Repeated point and period prevalence survey strategies.
setting. University-affiliated primary and tertiary care center.
methods. Analysis of data collected from 2006 to 2012 from annual HAI prevalence surveys using definitions proposed by the US
Centers for Disease Control and Prevention. The study design allowed the analysis of the same data in the format of a point or a period
prevalence survey.
results. Pooled point and period HAI prevalence was 7.46% and 9.84% (32%), respectively. This additional 32% was mainly attributable
to infections of the lower respiratory tract (2.42% vs 3.20% [32%]) and the urinary tract (1.76% vs 2.62% [49%]). Differences in
surgical site infections (1.02% vs 1.20% [19%]) and bloodstream infections (0.76% vs 0.86% [13%]) were smaller. HAI prevalence for
the point and period methodology in acute and long-term care were 7.47% versus 9.38 (26%) and 8.37% versus 11.89% (42%),
respectively. Differences were stable over time. Focusing on the 4 major HAIs (respiratory tract, urinary tract, surgical site, and bloodstream
infections) misses one-quarter of all HAIs.
conclusions. More HAIs are identified by the period prevalence method, especially those of shorter duration (lower respiratory and
urinary tract), which would make this method more suitable to be used in long-term care. Results of the 2 study methods cannot be
benchmarked against each other.
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The pioneering Study on the Efficacy of Nosocomial Infection
Control (SENIC) project, initiated in the 1970s by the US
Centers for Disease Control and Prevention (CDC), un-
equivocally proved the benefit of healthcare-associated infec-
tion (HAI) surveillance.1,2 The method was based on a strat-
ified random sample of patients from 338 US hospitals, and
HAIs were detected by thorough patient chart review. The
HAI prevalence at that time was estimated at approximately
5.2%.3-5 In 1970, the US National Nosocomial Infection Sur-
veillance network was established to provide regular pro-
spective outcome data on HAI in intensive care units (ICUs)
in the United States.6 In parallel, the CDC issued definitions
of nosocomial infections.7 Over the following decades, the
CDC HAI definitions were continually updated and became
the reference standard for the vast majority of HAI surveil-
lance activities around the world.7-14
In 1981, the World Health Organization (WHO) convened
an advisory group on the surveillance, control, and preven-
tion of HAI.15 The group specifically recommended the con-
duct of HAI prevalence surveys to assess the burden of the
problem in different parts of the world. Later, WHO pub-
lished prevalence data gathered between 1983 and 1985 from
47 hospitals in 14 countries.15 At the same time, an increasing
number of countries started to conduct national or regional
prevalence surveys. Most recently, the European Centre for
Disease Prevention and Control (ECDC), as well as the CDC,
performed large point prevalence surveys in Europe and the
United States based on the methodology published in 2 pilot
studies, and the results of the ECDC point prevalence survey
are now published.16-18 Most local, regional, and national sur-
veys used the point prevalence methodology, that is, only
HAIs active on the day of the survey were taken into account.
However, some studies in Italy,19,20 Switzerland,21-25 and the
United States26 used the period prevalence method, that is,
not only were HAIs active on the day of the survey accounted
for, but those active during a predefined period before the
survey day were also assessed (Figure 1). Some surveys, such
as the first Spanish prevalence survey of the Estudio de Prev-
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figure 1. The concepts of point and period prevalence surveys. In point prevalence surveys, all patients present on the day of prevalence
are eligible, and only healthcare-associated infections active at the time of the survey are included in the analysis. In this example, 2 of 16
patients have a healthcare-associated infection, for a prevalence of 12.5%. In period prevalence surveys, all patients present on the day of
prevalence are eligible, and healthcare-associated infections active at the time of the survey or in the preceding 6 days (for a total of 7 days
of study) are included in the analysis. In this example, 4 of 16 patients have a healthcare-associated infection, for a prevalence of 25%.
alencia de las Infecciones Nosocomiales en Espana (EPINE)
network, combined point prevalence (active infection on the
day of survey) with extrinsic risk factors present in the 7 days
before the survey.27 Both methodologies have advantages and
disadvantages. While a period prevalence survey will allow
capture of more HAIs, especially those of short duration, it
is methodologically “less pure,” since it mixes the concepts
of prevalence and incidence, and it is also more time-con-
suming than a pure point prevalence survey.
To our knowledge, no study has analyzed the differences
between the point and period methodology to assess the bur-
den of HAI. We conducted this study to provide such an
analysis from a large database and to place the findings in
the context of the published literature.
methods
The University of Geneva Hospitals (Geneva, Switzerland) is
a primary and tertiary care center with 1,908 beds; in 2012,
47,000 admitted patients accumulated 670,000 patient-days.
Located at 8 different sites, the hospital offers intensive, acute,
and long-term inpatient care and also includes a pediatric
hospital. Since 1994, the infection control team has conducted
annual period prevalence surveys in May and early June.28
The current study focused on data collected from 2006 to
2012 from all departments except psychiatry. All types of HAI
as defined by the CDC were included apart from asymptom-
atic urinary tract infection (UTI).11,12 No adjustments or mod-
ifications of the definitions or other aspects of the method-
ology were made during the study period, and all staff
involved in the survey were trained in the methodology.
Every patient present in the ward on the day of the prev-
alence survey was included except those admitted on the
calendar day of the survey. Infection control nurses and phy-
sicians screened patient charts for clinical symptoms and
signs, laboratory data, microbiological results, and infor-
mation from other diagnostics suggestive for infection within
a 1-week period, ending with the day of the prevalence survey.
HAIs were counted when they were active at any time within
the 1-week period (Figure 1).28 An infection was considered
active when the patient had clinical symptoms and/or was
still receiving treatment for that infection. Surgical site in-
fections were documented as healthcare associated when they
occurred within 30 days after the operation or 1 year in the
case of infection associated with the insertion of a prosthetic
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table 1. Patient Characteristics with Annual Trends: Prevalence Surveys, University of
Geneva Hospitals, 2006–2012
Characteristic Pooled data Trend, IRR (95% CI)
Age, median (IQR), years 72 (50–83) 1.01 (1.01–1.01)
Sex (female) 5,774 (56) 1.00 (0.99–1.02)
Charlson comorbidity index, mean  SD 1.17  1.68 1.01 (1.00–1.02)
McCabe score, mean  SD 1.19  0.46 1.01 (1.00–1.02)
Surgery 2,554 (25) 1.01 (0.99–1.03)
ICU stay at any time 853 (8) 1.07 (1.03–1.10)
Distribution of acute and long-term care
Acute care at prevalence 5,717 (55) 1.00 (0.99–1.02)
Long-term care at prevalence 4,650 (45) 1.00 (0.98–1.01)
note. Data are no. (%), unless otherwise indicated. CI, confidence interval; ICU, intensive
care unit; IQR, interquartile range; IRR, incidence rate ratio; SD, standard deviation.
device.21 The distinction between point and period prevalence
was possible because the data set contained a variable indi-
cating whether an HAI was active on the day of the prevalence
survey. Annual prevalence surveys are part of a quality im-
provement program promoted by the directorate of the Uni-
versity of Geneva Hospitals. The institutional ethics com-
mittee waived informed consent related to the prevalence
surveys. HAI duration was estimated from the pooled data
by the difference of days between the date of HAI onset and
the date of the point prevalence survey.
PubMed was searched for published prevalence surveys
without restrictions of language up to June 30, 2013. The
following search term was used: (“prevalence” [Title] OR
“point-prevalence” [Title] OR “cross-sectional” [Title]) AND
(“nosocomial” [Title] OR “hospital-acquired” [Title] OR “in-
fection in hospitals” [Title] OR “hospital infection” [Title]
OR “hospital infections” [Title] OR “healthcare-associated”
[Title] OR “hospital-associated” [Title] OR “infections
among hospitalized patients” [Title]). Further references were
obtained by a full text sift of retrieved publications.
Statistical Analysis
The descriptive analysis was stratified by CDC infection cat-
egories (lower respiratory tract infection and pneumonia
[LRTI], UTI, surgical site infection [SSI], bloodstream infec-
tion and clinical sepsis [BSI], gastrointestinal infection [GI],
skin and soft-tissue infection [SST], and other infections,
which included mostly eye, ear, nose, and throat infections)
and care settings (acute [including intensive care] and long-
term care). Descriptive statistics were used to express the
difference between point and period prevalence surveys. No
formal statistical test was used to quantify the differences
because the same database was used to calculate outcomes
for both point and period prevalence (the null hypothesis
that the prevalence obtained by the different methodologies
is equivalent can be rejected without a test since the period
prevalence contains all infections counted in the point prev-
alence). Differences for the different HAIs between acute and
long-term care were analyzed using a simple x2 test. Trends
related to patient characteristics across the study years were
determined using a nonadjusted Poisson regression analysis
for each separate variable and reported as incidence rate ra-
tios. Two-sided a ! .05 was used to determine statistical
significance. All statistical analyses were conducted using Stata
software, version 10.0 (StataCorp).
results
A total of 7 annual prevalence surveys including 10,367 pa-
tients were analyzed. Patient characteristics such as sex, age,
Charlson comorbidity index, surgery, and distribution among
the different care settings are summarized in Table 1. We
observed moderate yearly trends toward higher age, higher
McCabe classification29 and Charlson comorbidity index30
scores, and more frequent ICU stays. Proportions of acute
and long-term care did not change during the study period
(Table 1).
The point and period prevalence surveys identified a total
of 816 and 1,089 HAIs among 773 and 1,020 patients, re-
spectively. Estimated HAI durations (median [interquartile
range]) for LRTI, UTI, SSI, BSI, GI, SST, and other infections
were 6 (3–10) days, 5 (3–9) days, 14.5 (6–29) days, 7 (3–12)
days, 6.5 (3–11) days, 6 (4–13) days, and 7.5 (5–15) days,
respectively.
The pooled point and period prevalence (95% confidence
interval) of all HAIs were 7.46% (6.96%–7.98%) and 9.84%
(9.27%–10.42%), respectively. Figure 2 summarizes the dif-
ferences of pooled HAI prevalence between acute and long-
term care. Significantly higher proportions of UTI and LRTI
were identified in long-term care, while the proportions of
SSI and BSI were higher in acute care, irrespective of the
prevalence methodology. Table 2 summarizes the differences
between pooled point and period prevalence surveys for HAI,
LRTI, UTI, SSI, BSI, GI, SST, and other infections stratified
into acute and long-term care. Overall, HAI ratios were higher
(33.4%) when assessed by the period prevalence method
in both acute (25.6%) and long-term (42.1%) care. There
were particularly large differences between the 2 methodol-
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figure 2. Pooled point and period prevalence of healthcare-
associated infections (HAIs) with 95% confidence intervals stratified
by clinical setting: prevalence surveys, University of Geneva Hos-
pitals, 2006–2012. A, Point prevalence. B, Period prevalence. BSI,
bloodstream infection; GI, gastrointestinal infection; LRTI, pneu-
monia/lower respiratory tract infection; SSI, surgical site infection;
SST, skin and soft-tissue infection; UTI, urinary tract infection.
ogies for LRTI and UTI in long-term care where more of
these infections were identified. SSIs and BSIs were identified
mostly in acute care with little difference between point and
period prevalence.
Focusing on the 4 leading HAIs (LRTI, UTI, SSI, and BSI)
misses a high proportion of infections in both the point
(24.3%) and the period prevalence (25.0%), respectively. Dif-
ferences are larger in long-term than acute care in both the
point (33.0% vs 19.7%) and the period prevalence (28.0% vs
21.9%). The difference between the 2 settings is more pro-
nounced in the point than in the period prevalence.
Results of the Literature Search
The search term identified 305 publications, of which 249
were prevalence surveys or complementary material. An ad-
ditional 4 studies were identified by a search of the references
of retrieved publications. A total of 97 international, national,
or regional multicenter (more than 1 center) published sur-
veys were identified with an upward trend over the decades.
discussion
Our study shows that benchmarking between point and pe-
riod prevalence data is not possible, as the higher proportion
of infections identified by the period methodology favors
HAIs of short duration and infections in long-term care.
Prevalence surveys are biased in favor of HAIs of longer du-
ration compared with incidence surveys and are notably in-
fluenced by the duration of antimicrobial treatment and the
propensity to discharge patients.4 The period prevalence
methodology counterbalances this to some degree, and the
proportion of the different HAIs becomes more similar to
the proportion of their incidence.
From a methodological point of view, the idea of the period
prevalence may be challenged because it mixes the concepts
of prevalence and incidence (J. Freeman, personal commu-
nication, 1999). However, the period methodology should not
be considered inferior to the point prevalence methodology
on the basis of this aspect alone, and our data suggest that
it could be of particular interest for use in long-term care
settings where HAIs of short duration, such as LRTI and UTI,
are common and where the burden of these HAIs may be
underestimated when using the point prevalence method. The
difference between the 2 methodologies in acute care settings,
where more SSIs and BSIs occur, is less important. Period
prevalence data do not serve to estimate incidence rates using
common algorithms.31-33 The better approximation of HAIs
of short duration by the period methodology could add value
to such models, but further studies are needed to validate
this hypothesis. Furthermore, focusing on the 4 leading (ie,
most frequent) HAIs (LRTI, UTI, SSI, and BSI) may reduce
workload but underestimates the proportion of infections
(such as GI, SST, eye, and ear, nose, and throat infections)
that are common in long-term care. This makes such an
approach unsuitable for this type of setting, and prevalence
surveys in long-term care should better focus on a more
appropriate selection of HAIs, such as LRTI, UTI, SSI, and
SST34 or LRTI, UTI, BSI, GI, and conjunctivitis.35
HAI incidence data have become the gold standard of HAI
surveillance over the past 2 decades. National and multi-
national networks, such as the US National Healthcare Safety
Network, the German Krankenhaus Infektions Surveillance
System, and the International Nosocomial Infection Control
Consortium, have become success stories both in high-income
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table 2. Distribution of Pooled Point and Period Prevalence of Healthcare-Associated Infections (HAIs)
Stratified by Clinical Setting: Prevalence Surveys, University of Geneva Hospitals, 2006–2012
Clinical setting, type of infection No. (%)
Point prevalence,a
% (95% CI) No. (%)
Period prevalence,a
% (95% CI)
Hospital-wide (10,367 patients)
LRTI 251 (31) 2.42 (2.13–2.74) 332 (30) 3.20 (2.87–3.56)
UTI 182 (22) 1.76 (1.51–2.03) 272 (25) 2.62 (2.32–2.95)
SSI 106 (13) 1.02 (0.84–1.24) 124 (11) 1.20 (1.00–1.42)
BSI 79 (10) 0.76 (0.60–0.95) 89 (8) 0.86 (0.69–1.06)
GI 58 (7) 0.56 (0.43–0.72) 87 (8) 0.84 (0.67–1.03)
SST 50 (6) 0.48 (0.36–0.64) 68 (6) 0.66 (0.51–0.83)
Other 90 (11) 0.87 (0.70–1.07) 117 (11) 1.13 (0.93–1.35)
All HAI 816 (100) 7.87 (7.36–8.41) 1,089 (100) 10.50 (9.92–11.11)
Acute care (5,717 patients)
LRTI 120 (28) 2.10 (1.74–2.50) 143 (27) 2.50 (2.11–2.94)
UTI 57 (13) 1.00 (0.76–1.29) 88 (16) 1.54 (1.24–1.89)
SSI 103 (24) 1.80 (1.47–2.19) 119 (22) 2.08 (1.73–2.49)
BSI 63 (15) 1.10 (0.85–1.41) 69 (13) 1.21 (0.94–1.52)
GI 35 (8) 0.61 (0.43–0.85) 45 (8) 0.79 (0.57–1.05)
SST 14 (3) 0.24 (0.13–0.41) 22 (4) 0.38 (0.24–0.58)
Other 35 (8) 0.61 (0.43–0.85) 50 (9) 0.87 (0.65–1.15)
All HAI 427 (100) 7.47 (6.80–8.18) 536 (100) 9.38 (8.63–10.16)
Long-term care (4,650 patients)
LRTI 131 (34) 2.82 (2.36–3.33) 189 (34) 4.06 (3.52–4.67)
UTI 125 (32) 2.69 (2.24–3.19) 184 (33) 3.96 (3.42–4.56)
SSI 3 (1) 0.06 (0.01–0.19) 5 (1) 0.11 (0.03–0.25)
BSI 16 (4) 0.34 (0.20–0.56) 20 (4) 0.43 (0.26–0.66)
GI 23 (6) 0.49 (0.31–0.74) 42 (8) 0.90 (0.65–1.22)
SST 36 (9) 0.77 (0.54–1.07) 46 (8) 0.99 (0.72–1.32)
Other 55 (14) 1.18 (0.89–1.54) 67 (12) 1.44 (1.12–1.83)
All HAI 389 (100) 8.37 (7.59–9.20) 553 (100) 11.89 (10.98–12.86)
note. CI, confidence interval; BSI, bloodstream infection; GI, gastrointestinal infection; LRTI, pneu-
monia/lower respiratory tract infection; SSI, surgical site infection; SST, skin and soft-tissue infection;
UTI, urinary tract infection.
a Infections divided by the total number of patients.
and in low- and middle-income countries, thus serving as a
reference for many similar undertakings.36-38 Prospective hos-
pital-wide HAI incidence surveillance is time-consuming and
costly, and such programs are often restricted to the ICU or
other high-risk settings, such as oncology or neonatology. How-
ever, HAI is not exclusively confined to such high-risk areas;
it also occurs in regular wards. For example, it has been shown
that central line–associated BSIs occur at similar incidence rate
ratios both in and outside the ICU.39
Prevalence surveys help to assess the burden of hospital-
wide HAI at a reasonable cost.40-42 In the 1970s, many coun-
tries and regions in Europe and elsewhere began to conduct
prevalence surveys, and the CDC and the ECDC have now
followed this example by launching large point prevalence
surveys in the United States and Europe.18 Table 3 and Figure
3 show when countries and regions started to conduct in-
ternational, national, or regional prevalence surveys, spanning
a timeline of 4 decades. Only a few prevalence surveys used
the period methodology,19-26,43 and the vast majority in Af-
rica,44-50 Asia,51-64 Australasia,65-67 Europe,34,40,42,68-110 North
America,17,111-113 and South America114-117 used the point prev-
alence methodology. Although many surveys used some ver-
sion of the CDC HAI definitions, methodological inequalities
make direct comparison of prevalence results difficult.118
The history of HAI prevalence surveys is linked to the
meticulous work of the SENIC project in the 1970s and the
useful HAI definitions issued and regularly updated by the
CDC and the ECDC, which have served the infection control
community for many years. Today, time and budget restric-
tions force infection control programs to reestablish the con-
cept of the prevalence survey, despite its methodological lim-
itations. The recent commitment of the CDC and the ECDC
to prevalence surveys sets the stage for future prevalence stud-
ies using comparable methodologies. More than 30 years after
it was issued, the WHO call for action to perform HAI prev-
alence surveys to assess the size of the problem in different
parts of the world is finally established.15
In summary, our findings suggest that the additional por-
tion of HAIs detected by the period methodology favors HAIs
of short duration, which are less likely to be captured by the
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table 3. First International, National, or Regional Prevalence Surveys of Healthcare-Associated Infections: 1970–2010
Country/organization
Year(s)
of survey Hospitals Patients Setting(s) CDC criteria Method Prevalence,a %
Sweden69 1975 5 4,246 All Yes7 Point 17.0
Denmark70 1978 20/25 2,920 Acute Yes8 Point 10.4
United Kingdom75 1979 43 18,163 Acute Yes10 Point 19.1
Italy68 1983 130 34,577 Acute Yes8 Point 19.3
WHO15 1983–1985 47 28,861 Acute No Point 8.7
Australia65 1984 269 28,643 Acute Yes10,119 Point 6.3
Belgium76 1984 106 8,723 Acute Yes8 Pointb 9.3
Czechoslovakia105 1984 23 12,260 All No120 Point 6.1
Thailand53 1988 23 6,805 Acute No121 Point 11.7
Spain27,122 1990 123 38,489 Acute Yes11 Pointc 8.5
Norway78 1991 76 14,977 Acute Yes9 Pointd 6.3
Brazil114 1992 11 2,339 Acute Yes11 Point 14.0
Europe85 1992 1,417 10,038 ICU Yes11 Point 44.8
Mauritius50 1992 4 1,190 Acute Yes10 Point 4.9
Germany94 1995 72 14,996 Acute Yes11 Point 3.5
France82 1996e 830 236,334 All Yes14 Point 6.7
New Zealand66,67 1996–1999 4 5,819 All Yes11 Point 9.5
Switzerland21 1996 4 1,349 Acute Yes11 Period 11.6
Cuba116 1997 28 6,152 Acute Yes11,14 Point 6.8
Lebanon62 1997 14 834 Acute Yes119,123 Point 6.8
Greece102 1999 14 3,925 Acute Yes11,14 Point 9.3
Mexico112 1999f 21 1,183 Pediatric Yes Point 9.8
Slovenia106 2001 19 6,695 Acute Yes11,14 Point 4.6
Turkey103 2001 22 236 ICU Yes11 Point 48.7
Canada113 2002 25 5,750 Acute Yes Pointg 10.5
Indonesia63 2001–2002 2 888 Acute Yes11,14 Pointh 8.3
Latvia98 2003f 2 1,291 Acute NA Point 5.6
Iran60 2004–2005 8 2,667 All Yes11 Point 8.8
Finland80 2005 30 8,234 Acute Yes11 Point 8.5
Scotland91 2005–2006 45i 11,608 Acute Yes Point 9.5
Ireland87 2006 44 7,541 Acute Yes13 Point 4.9
China61 2007–2008 13 20,350 Acute Yes11,j Point 3.9
Netherlands96 2007–2008 41 26,937 Acute Yesk Pointl 6.2
Argentina117 2008 39 4,249 Acute Yes124 Point 11.3
Mongolia58 2008 2 933 Acute Yes Point 5.4
Vietnam56 2008 36 7,571 Acute Yes11 Point 7.8
CDC17 2009 9 851 Acute Yes Point 6.0
ECDC18 2013 947 273,753 Acute Yes12,m Point 6.0
note. BSI, bloodstream infection; CDC, US Centers for Disease Control and Prevention; CDI, Clostridium difficile
infection; ECDC, European Centre for Disease Prevention and Control; ICU, intensive care unit; NA, not available;
SSI, surgical site infection; UTI, urinary tract infection; WHO, World Health Organization.
a Proportion of patients with 1 or more healthcare-associated infections as defined in the survey.
b Only UTI, SSI, and BSI.
c Extrinsic risk factors were screened for 7 days before the survey.
d All diagnoses except UTIs were based on clinical criteria alone.
e A first study among 11,599 patients in 39 hospitals was performed in 1990.125
f Year of publication.
g Only UTI, BSI, SSI, and CDI.
h Only UTI, BSI, SSI, and phlebitis.
i Acute care only.
j With some modifications for infants.
k With some modifications.
l Only UTI, pneumonia, BSI, and SSI.
m European case definitions by HELICS or other European projects were used where available.
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figure 3. International, national, or regional prevalence surveys of healthcare-associated infections in acute or mixed care settings: 1970–
2013.
point methodology. This would make the period strategy suit-
able to be used in long-term care, while the benefit in acute
care is low. The results of the 2 concepts cannot be bench-
marked against each other. Given the potential advantage of
the period methodology in long-term care and the hetero-
geneity of care settings in our primary and tertiary care hos-
pital, we will continue to use the period methodology with
the opportunity to calculate point prevalence data in order
to benchmark with other databases.
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